Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
Crossref DOI link: https://doi.org/10.1007/s40272-017-0266-9
Published Online: 2017-10-27
Published Print: 2018-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Cozijnsen, M. A.
Samsom, J. N.
de Ridder, L. http://orcid.org/0000-0002-6035-1182
License valid from 2017-10-27